A rise in virus cases in Israel has prompted the government to re-impose restrictions on activity, including mask mandates and vaccine certification for large events. There are signs that the Pfizer vaccine may be much less effective at preventing infection against the Delta variant and that vaccine efficacy fades over time, prompting the introduction of booster jabs. So far there is little evidence to suggest that the vaccine is much less effective at preventing severe illness. While the re-opening of international tourism is likely to be delayed, restrictions on the domestic economy look set to remain light-touch.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to gain:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services